← Leaderboards
Jane C Burns
University Of California San Diego
$14,170,537
Attributed
$18,364,271
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$16,923,327 · 8
FDA$1,440,944 · 1
By mechanism
R01$12,703,357 · 4
R33$2,924,117 · 1
R61$1,756,336 · 1
K24$525,586 · 1
R21$424,875 · 1
R13$30,000 · 1
Top collaborators
- Adriana H Tremoulet7 shared
- Harold M Hoffman6 shared
- John Y-J Shyy6 shared
- Alessandra I Franco4 shared
Most similar at University Of California San Diego
Same institution · by research overlap
- Douglas D Richman$67,820,652
- Eyal Raz$14,631,538
Others in their field
Top investigators on “Mucocutaneous Lymph Node Syndrome”
- Moshe Arditi · Cedars-Sinai Medical Center$7,603,143
- Anne H Rowley · Northwestern University$7,310,835
- Magali Noval Rivas · Cedars-Sinai Medical Center$5,639,049
- Adriana H Tremoulet · University Of California, San Diego$3,267,343
- Timothy A Springer · Boston Children'S Hospital$2,811,726
- Maria Virginia Pascual · University Of Texas Sw Med Ctr/Dallas$2,419,315
Research focus
Mucocutaneous Lymph Node SyndromeChildAcuteChildhoodPathogenesisInflammatoryMolecularImmune ResponseCoronary ArteryVasculitisFeverAneurysmFundingWhole BloodLeadResponseSamplingEtiologyPlasmaBaseProteinsTranscriptClinical TrialsLink
Grant awards (37)
Diagnosing and predicting risk in children with SARS-CoV-2- related illness$1,274,998
R33 · FY2023 · HD · contact PI
Diagnosing and predicting risk in children with SARS-CoV-2- related illness$1,238,182
R33 · FY2023 · HD · contact PI
Diagnosing and predicting risk in children with SARS-CoV-2- related illness$410,937
R33 · FY2023 · HD · contact PI
Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki Disease$729,091
R01 · FY2022 · HL · contact PI
Diagnosing and predicting risk in children with SARS-CoV-2- related illness$657,921
R61 · FY2022 · HD · contact PI
Diagnosing and predicting risk in children with SARS-CoV-2- related illness$400,000
R61 · FY2022 · HD · contact PI
Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki Disease$730,641
R01 · FY2021 · HL · contact PI
Diagnosing and predicting risk in children with SARS-CoV-2- related illness$698,415
R61 · FY2021 · HD · contact PI
Endothelial Cell and Cardiomyocyte Dysfunction in Children with Kawasaki disease-like SARS-CoV-2 Induced Immune Activation$727,650
R01 · FY2020 · HL · contact PI
Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki Disease$716,260
R01 · FY2020 · HL · contact PI
Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki Disease$710,525
R01 · FY2019 · HL · contact PI
Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki Disease$715,175
R01 · FY2018 · HL · contact PI
Impact of TNFa blockade on immune function in acute Kawasaki disease$327,630
R01 · FY2013 · HL
Impact of TNFa blockade on immune function in acute Kawasaki disease$382,388
R01 · FY2012 · HL
Phase III infliximab for primary treatment of Kawasaki disease IND 11046 6/27/200$373,206
R01 · FY2012 · FD · contact PI
Impact of TNFa blockade on immune function in acute Kawasaki disease$386,250
R01 · FY2011 · HL
Phase III infliximab for primary treatment of Kawasaki disease IND 11046 6/27/200$356,991
R01 · FY2011 · FD · contact PI
Genetic Markers and gene expression in Kawasaki Disease$735,130
R01 · FY2010 · HL · contact PI
Impact of TNFa blockade on immune function in acute Kawasaki disease$386,250
R01 · FY2010 · HL
Phase III infliximab for primary treatment of Kawasaki disease IND 11046 6/27/200$352,480
R01 · FY2010 · FD · contact PI
Genetic Markers and gene expression in Kawasaki Disease$731,468
R01 · FY2009 · HL · contact PI
Genetic influences and T-cell activation in Kawasaki Disease$193,125
R21 · FY2009 · HL · contact PI
Genetic Markers and gene expression in Kawasaki Disease$701,156
R01 · FY2008 · HL · contact PI
Phase III infliximab for primary treatment of Kawasaki disease IND 11046 6/27/200$358,267
R01 · FY2008 · FD · contact PI
Genetic influences and T-cell activation in Kawasaki Disease$231,750
R21 · FY2008 · HL · contact PI
Matrix Metalloproteinases in Kawasaki Disease$109,801
K24 · FY2008 · HL · contact PI
Genetic Markers and gene expression in Kawasaki Disease$701,575
R01 · FY2007 · HL · contact PI
Matrix Metalloproteinases in Kawasaki Disease$107,391
K24 · FY2007 · HL · contact PI
Genetic Markers and gene expression in Kawasaki Disease$61,553
R01 · FY2007 · HL · contact PI
Genetic Markers and gene expression in Kawasaki Disease$760,338
R01 · FY2006 · HL · contact PI
Matrix Metalloproteinases in Kawasaki Disease$105,049
K24 · FY2006 · HL · contact PI
Matrix Metalloproteinases in Kawasaki Disease$102,776
K24 · FY2005 · HL
8th International Kawasaki Disease Symposium$30,000
R13 · FY2005 · HL
Genetic Influences &Gene Expression in Kawasaki Disease$586,704
R01 · FY2004 · HL
Matrix Metalloproteinases in Kawasaki Disease$100,569
K24 · FY2004 · HL
Genetic Influences &Gene Expression in Kawasaki Disease$570,403
R01 · FY2003 · HL
Genetic Influences &Gene Expression in Kawasaki Disease$602,226
R01 · FY2002 · HL